α-Glucosidase and PTP1B are the key targets to treat diabetes and obesity [9] and compounds with dual inhibitory activity against these enzymes exhibit synergistic effects to prevent hyperglycaemia, in turn, effectively improve insulin sensitization [10]. Here, INS is linked to obesity disorder.